Status | Study |
NOT_YET_RECRUITING |
Study Name: Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome Condition: Schnitzler Syndrome Date: 2019-10-22 Interventions: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial |
Not yet recruiting |
Study Name: Tocilizumab in Patients With Schnitzler's Syndrome Condition: Schnitzler's Syndrome Date: 2017-01-05 Interventions: Drug: Tocilizumab Tocilizumab 162mg 1x weekly s.c. O |
Active, not recruiting |
Study Name: Ilaris® Effects in Schnitzler Syndrome (ILESCH) Condition: Schnitzler Syndrome Date: 2011-07-07 Interventions: Drug: Canakinumab 150mg subcut |
Completed |
Study Name: Efficacy and Safety of Canakinumab in Schnitzler Syndrome Condition: Schnitzler Syndrome Date: 2011-01-12 Interventions: Drug: Canakinumab Monthly subcutaneous injection with 150mg Canakinumab for 6 months |
Completed |
Study Name: Ilaris (Canakinumab) in the Schnitzler Syndrome Condition: Schnitzler Syndrome Date: 2010-11-19 Interventions: Drug: Ilaris Canakinumab 1 |
Completed |
Study Name: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) Condition: Muckle-Wells Syndrome Schnitzler Syndrome Date: 2010-01-07 Interventions: Drug: rilonacept 160mg of rilonacept 1x/week Other N |
Active, not recruiting |
Study Name: Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors Condition: Schnitzler Syndrome Date: 2009-07-03 |
Completed |
Study Name: The Efficacy and Safety of ITF2357 in AIS Condition: Autoinflammatory Syndromes HIDS TRAPS Date: 2007-02-28 Interventions: Drug: ITF2357 |